Remestemcel-L reduces ARDS mortality in those under 65 years old
New data shows patients with COVID-19-related Acute Respiratory Distress Syndrome…
New data shows patients with COVID-19-related Acute Respiratory Distress Syndrome (ARDS) were up to 75 percent less likely to die when treated with remestemcel-L and dexamethasone.